Wealth Enhancement Trust Services
SPRY icon

Wealth Enhancement Trust Services’s ARS Pharmaceuticals SPRY Stock Holding History

Wealth Enhancement Trust Services’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2
Closed -$16 – 1420
2026
Q2 		$16 Buy
+2
New +$17 ﹤0.01% 1509

Other funds holding SPRY

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Tyro Capital Management
Tyro Capital Management Miami, Florida $564M AUM 72.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return
Creek Drive Management Group
Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

Wealth Enhancement Trust Services's SPRY Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 2 shares — an estimated $16 sold.

Wealth Enhancement Trust Services first reported a position in SPRY in Q2 2026 and held it in 1 quarter. The position peaked at $16 in Q2 2026. 133 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 2 ARS Pharmaceuticals shares in Q3 2026, an estimated $16.
  • Wealth Enhancement Trust Services first reported a position in ARS Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's ARS Pharmaceuticals position peaked at $16 in Q2 2026.
  • 133 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.